Business News

    Radiopharm Theranostics (ASX:RAD) announces FDA meeting supports an IND application

    Article Image

    Radiopharm Theranostics (ASX:RAD) has reported a positive pre-Investigational New Drug (IND) meeting with the US FDA for its product F18-pivalate (RAD 101).

    The radiopharmaceutical developer said following the FDA's guidance, the company plans to file an IND application for a multi-centre trial during Q3 2023 for imaging brain metastasis.

    RAD 101, an imaging agent targeting fatty acid synthetase, aims to monitor cerebral metastasis, with approximately 300,000 patients diagnosed each year in the US.

    Radiopharm Theranostics has an exclusive global license for the pivalate platform technology and collaborates with the Imperial College of London for further development.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa